• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Russell 2000 Marks Fifth Day Of Gains: What's Driving Surge In Small-Cap Stocks?

    7/16/24 5:01:15 PM ET
    $AIT
    $FTAI
    $LNTH
    Industrial Specialties
    Consumer Discretionary
    Misc Corporate Leasing Services
    Industrials
    Get the next $AIT alert in real time by email

    FTAI Aviation Ltd. (NYSE:FTAI) and Applied Industrial Technologies, Inc. (NYSE:AIT) were among small-cap stocks moving higher on Tuesday as the Russell 2000 Index had a fifth straight day of gains.

    The iShares Russell 2000 ETF (NYSE:IWM) gained 3.41% on Tuesday, ushering the index to a cumulative gain of over 9% across the last five sessions. This remarkable streak represents the Russell 2000's best five-day performance since June 2020.

    FTAI Aviation, a provider of aircraft operations and engine maintenance, rose 5.63% to close at $107.42 on Tuesday, while Applied Industrial gained 4.63% to $210.59.

    Also Read: Russell 2000 Rallies To 16-Month Highs: Best Performing Small-Cap Stocks Popping Over 80% In December

    FTAI Aviation accounts for 0.39% of the iShares Russell 2000 ETF, while Applied Industrial makes up 0.29% share, according to iShares by BlackRock.

    Individual stocks in the ETF that countered Tuesday’s small-cap advancement include Lantheus Holdings, Inc. (NASDAQ:LNTH), which fell 3.97% to $118.30.

    The rapid rise of small caps is attributed to the growing conviction that the Federal Reserve will lower interest rates at its September meeting. The Russell 2000 rally kicked off last week, driven by June inflation data coming in below expectations, sparking traders' speculation about rate cuts.

    According to the CME Group's FedWatch Tool, fed futures now indicate a full 100% probability of an interest rate cut in nearly two months, marking the first reduction in borrowing costs since 2020. On Monday, Fed Chair Jerome Powell struck a dovish tone, acknowledging that recent inflation reports bolster confidence in returning to the 2% target, effectively hinting at forthcoming rate cuts.

    Read Now:

    • Russell 2000 Vs. S&P 500: Turning Tide For Small Caps? ‘Risk-Reward Trade-Off Is Very Skewed’

    Don’t miss the opportunity to dominate in a volatile market at the Benzinga SmallCAP Conference on Oct. 9-10 at the Chicago Marriott Downtown Magnificent Mile. Get exclusive access to CEO presentations, 1:1 meetings with investors, and valuable insights from top financial experts. Whether you’re a trader, entrepreneur, or investor, this event offers unparalleled opportunities to grow your portfolio and network with industry leaders. Secure your spot and get your tickets today!

    Image created using artificial intelligence via Midjourney.

    Get the next $AIT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AIT
    $FTAI
    $LNTH

    CompanyDatePrice TargetRatingAnalyst
    Lantheus Holdings Inc.
    $LNTH
    2/26/2026Mkt Perform → Outperform
    William Blair
    Lantheus Holdings Inc.
    $LNTH
    12/12/2025$80.00Hold → Buy
    Truist
    Lantheus Holdings Inc.
    $LNTH
    10/8/2025$77.00Buy → Neutral
    Goldman
    Applied Industrial Technologies Inc.
    $AIT
    8/15/2025Outperform → Mkt Perform
    Raymond James
    Lantheus Holdings Inc.
    $LNTH
    8/12/2025$63.00Buy → Hold
    Truist
    FTAI Aviation Ltd.
    $FTAI
    5/2/2025$123.00Hold → Buy
    Stifel
    FTAI Aviation Ltd.
    $FTAI
    3/3/2025$100.00 → $123.00Buy → Hold
    Stifel
    FTAI Aviation Ltd.
    $FTAI
    1/10/2025$190.00Peer Perform → Outperform
    Wolfe Research
    More analyst ratings

    $AIT
    $FTAI
    $LNTH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lantheus Holdings upgraded by William Blair

    William Blair upgraded Lantheus Holdings from Mkt Perform to Outperform

    2/26/26 12:20:43 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Lantheus Holdings upgraded by Truist with a new price target

    Truist upgraded Lantheus Holdings from Hold to Buy and set a new price target of $80.00

    12/12/25 8:36:54 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Lantheus Holdings downgraded by Goldman with a new price target

    Goldman downgraded Lantheus Holdings from Buy to Neutral and set a new price target of $77.00

    10/8/25 8:24:33 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $AIT
    $FTAI
    $LNTH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    FTAI Aviation Ltd. Announces Timing of First Quarter 2026 Earnings and Conference Call

    NEW YORK, April 01, 2026 (GLOBE NEWSWIRE) -- FTAI Aviation Ltd. (NASDAQ:FTAI, the ", Company", or "FTAI")) plans to announce its financial results for the first quarter 2026 after the closing of Nasdaq on Wednesday, April 29, 2026. A copy of the press release and an earnings supplement will be posted to the Investor Relations section of the Company's website, https://www.ftaiaviation.com/. In addition, management will host a conference call on Thursday, April 30, 2026 at 8:00 A.M. Eastern Time. The conference call may be accessed by registering via the following link https://register-conf.media-server.com/register/BI473c73de9b164133be498d6715eae345. Once registered, participants will rece

    4/1/26 6:30:00 AM ET
    $FTAI
    Misc Corporate Leasing Services
    Industrials

    Lantheus Announces Three-Month Extension of PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs)

    BEDFORD, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or "Company") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced today that the U.S. Food and Drug Administration (FDA) has extended its review of the New Drug Application (NDA) for LNTH-2501 (Gallium 68 edotreotide) by three months to June 29, 2026.  The extension and revised target Prescription Drug User Free Act (PDUFA) goal date of June 29, 2026, will allow the FDA additional time to review and consider further manufacturing related information submitted by Lantheus. This stan

    3/17/26 4:01:00 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Lantheus Announces FDA Approval of PYLARIFY TruVu™ (piflufolastat F 18) Injection

    New formulation of its widely-used U.S. market-leading PSMA PET imaging agent combines thediagnostic performance of PYLARIFY® (piflufolastat F 18) with the potential for larger batches and greater patient availability PYLARIFY TruVu™ is expected to launch in 4Q 2026, with a phased geographic rollout to support a seamless customer transition BEDFORD, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that the U.S. Food and Drug Administration (FDA) has approved PYLARIFY TruVu (pifl

    3/6/26 4:01:00 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $AIT
    $FTAI
    $LNTH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Nam Eun bought $100,056 worth of Ordinary Shares (652 units at $153.46), increasing direct ownership by 8% to 9,089 units (SEC Form 4)

    4 - FTAI Aviation Ltd. (0001590364) (Issuer)

    11/14/25 4:16:17 PM ET
    $FTAI
    Misc Corporate Leasing Services
    Industrials

    Chief Operating Officer Moreno David bought $1,020,478 worth of Ordinary Shares (6,637 units at $153.76), increasing direct ownership by 0.99% to 233,906 units (SEC Form 4)

    4 - FTAI Aviation Ltd. (0001590364) (Issuer)

    11/13/25 4:35:25 PM ET
    $FTAI
    Misc Corporate Leasing Services
    Industrials

    CEO and Chairman Adams Joseph P. Jr. bought $311,820 worth of Ordinary Shares (2,000 units at $155.91), increasing direct ownership by 0.93% to 217,069 units (SEC Form 4)

    4 - FTAI Aviation Ltd. (0001590364) (Issuer)

    11/13/25 4:16:23 PM ET
    $FTAI
    Misc Corporate Leasing Services
    Industrials

    $AIT
    $FTAI
    $LNTH
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Lantheus Holdings Inc.

    SCHEDULE 13G/A - Lantheus Holdings, Inc. (0001521036) (Subject)

    3/27/26 10:20:31 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Applied Industrial Technologies Inc.

    SCHEDULE 13G/A - APPLIED INDUSTRIAL TECHNOLOGIES INC (0000109563) (Subject)

    3/26/26 3:42:37 PM ET
    $AIT
    Industrial Specialties
    Consumer Discretionary

    SEC Form DEFA14A filed by Lantheus Holdings Inc.

    DEFA14A - Lantheus Holdings, Inc. (0001521036) (Filer)

    3/20/26 4:16:35 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $AIT
    $FTAI
    $LNTH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Wallace Peter C

    4 - APPLIED INDUSTRIAL TECHNOLOGIES INC (0000109563) (Issuer)

    4/1/26 4:21:05 PM ET
    $AIT
    Industrial Specialties
    Consumer Discretionary

    Director Hannaway Judith A was granted 67 units of Ordinary Shares, increasing direct ownership by 2% to 3,267 units (SEC Form 4)

    4 - FTAI Aviation Ltd. (0001590364) (Issuer)

    3/17/26 4:30:55 PM ET
    $FTAI
    Misc Corporate Leasing Services
    Industrials

    Director Levison A Andrew was granted 88 units of Ordinary Shares, increasing direct ownership by 0.80% to 11,151 units (SEC Form 4)

    4 - FTAI Aviation Ltd. (0001590364) (Issuer)

    3/17/26 4:31:11 PM ET
    $FTAI
    Misc Corporate Leasing Services
    Industrials

    $AIT
    $FTAI
    $LNTH
    Leadership Updates

    Live Leadership Updates

    View All

    Lantheus Completes Acquisition of Life Molecular Imaging and Appoints Dr. Ludger Dinkelborg as Head of R&D

    BEDFORD, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ:LNTH), today announced the successful completion of its previously disclosed acquisition of Life Molecular Imaging Ltd. ("Life Molecular"), a subsidiary of Life Healthcare Group Holdings Ltd ("Life Healthcare"). As part of the acquisition, Ludger Dinkelborg, PhD, formerly CEO and Managing Director of Life Molecular Imaging, has been appointed Head of Research and Development at Lantheus effective August 1, 2025. "We are thrilled to welcome Dr. Dinkelborg and the entire Life Molecular team to Lantheus," said Brian Markison, CEO of Lantheus. "Ludger's proven leadership, scientific

    7/22/25 7:00:00 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    PharmaLogic Announces Appointment of Etienne Montagut as President and Chief Executive Officer

    BOCA RATON, Fla., June 2, 2025 /PRNewswire/ -- PharmaLogic Holdings Corp. ("PharmaLogic" or "the Company"), a leading contract development and manufacturing organization (CDMO) specialized in radiopharmaceuticals, today announces the Company has appointed Etienne Montagut, currently serving as President, to the position of President and Chief Executive Officer, effective as of 1 June 2025. Mr. Montagut brings over 25 years of senior leadership experience in the pharmaceutical sector, with a solid track record of driving growth and executing strategic transformation across glob

    6/2/25 8:00:00 AM ET
    $GEHC
    $LNTH
    Medical Electronics
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    Lantheus Appoints Phuong Khanh (P.K.) Morrow, M.D., as New Board Member

    BEDFORD, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Phuong Khanh (P.K.) Morrow, M.D. to Lantheus' Board of Directors ("Board"), effective February 1, 2025. Dr. Morrow is an experienced pharmaceutical executive and physician-scientist with deep expertise leading end-to-end clinical development in the field of oncology. As an independent director, Dr. Morrow will serve as a member of the Board's Science and Technology Committee, where her proven track record i

    1/30/25 8:30:00 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $AIT
    $FTAI
    $LNTH
    Financials

    Live finance-specific insights

    View All

    FTAI Aviation Ltd. Announces Timing of First Quarter 2026 Earnings and Conference Call

    NEW YORK, April 01, 2026 (GLOBE NEWSWIRE) -- FTAI Aviation Ltd. (NASDAQ:FTAI, the ", Company", or "FTAI")) plans to announce its financial results for the first quarter 2026 after the closing of Nasdaq on Wednesday, April 29, 2026. A copy of the press release and an earnings supplement will be posted to the Investor Relations section of the Company's website, https://www.ftaiaviation.com/. In addition, management will host a conference call on Thursday, April 30, 2026 at 8:00 A.M. Eastern Time. The conference call may be accessed by registering via the following link https://register-conf.media-server.com/register/BI473c73de9b164133be498d6715eae345. Once registered, participants will rece

    4/1/26 6:30:00 AM ET
    $FTAI
    Misc Corporate Leasing Services
    Industrials

    Lantheus Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    Worldwide revenue of $406.8 million and $1.54 billion for the fourth quarter and full year 2025GAAP fully diluted earnings per share of $0.82 and $3.41 for the fourth quarter and full year 2025Adjusted fully diluted earnings per share of $1.67 and $6.08 for the fourth quarter and full year 2025Repurchased $100 million of shares of common stock in the fourth quarter pursuant to the previously announced stock repurchase plan that was approved by the Board in July 2025Company announced today that it is sharpening its strategic focus to innovative radiodiagnostics and pursuing value‑maximizing alternatives for radiotherapeutic assets to support long-term growthCompany provides full year 2026 rev

    2/26/26 7:00:00 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    FTAI Aviation Ltd. Reports Fourth Quarter and Full Year 2025 Results, Increases Dividend to $0.40 per Ordinary Share

    NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- FTAI Aviation Ltd. (NASDAQ:FTAI) (the "Company" or "FTAI") today reported financial results for the fourth quarter and full year 2025. The Company's consolidated comparative financial statements and key performance measures are attached as an exhibit to this press release. Financial Overview       (in thousands, except per share data)    Selected Financial Results Q4'25  Net Income Attributable to Shareholders $        111,852          Basic Earnings per Ordinary Share $        1.09          Diluted Earnings per Ordinary Share $        1.08          Adjusted EBITDA (1) $        277,178               (1) For definitions and reconciliations of non

    2/25/26 4:15:00 PM ET
    $FTAI
    Misc Corporate Leasing Services
    Industrials

    $AIT
    $FTAI
    $LNTH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Lantheus Holdings Inc.

    SC 13G - Lantheus Holdings, Inc. (0001521036) (Subject)

    11/14/24 8:21:14 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13G/A filed by Lantheus Holdings Inc.

    SC 13G/A - Lantheus Holdings, Inc. (0001521036) (Subject)

    11/14/24 3:29:28 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G filed by FTAI Aviation Ltd.

    SC 13G - FTAI Aviation Ltd. (0001590364) (Subject)

    11/13/24 12:26:41 PM ET
    $FTAI
    Misc Corporate Leasing Services
    Industrials